HLAVNÍ TÉMA MASLD a její štíhlý fenotyp | 239 / Vnitř Lék. 2026;72(4):232-239 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212-1219. 2. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 1;48(7):1057-1082. 3. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL- -EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction- -associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. 4. Verdecchia P, Murdolo G, Coiro S, et al. Therapy of Type 2 diabetes: more gliflozines and less metformin? Eur Heart J Suppl. 2023;25(Suppl B):B171-B176. 5. Tilg H, Petta S, Stefan N, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026 Jan 13;335(2):163-174. 6. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-54.e1-9; quiz e39-40. 7. Li D, Zhang X. From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma. Hepatol Commun. 2025 Dec 1;9(12):e0846. 8. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835. 9. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. 10. Dey P. The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different? Front Endocrinol (Lausanne). 2025 Oct 20;16:1693123. 11. Zhang X, Lau HC, Yu J. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options. Pharmacol Rev. 2025;77(2):100018. 12. Fouad Y, Mostafa AM, Gomaa A, et al. Lean MASH: A High-Risk Subtype With Significant Cardiometabolic Burden. J Gastroenterol Hepatol. 2026 Feb;41(2):817-818. 13. Trifan A, Rotaru A, Stafie R, et al. Clinical and laboratory characteristics of normal weight and obese individuals with nonalcoholic fatty liver disease. Diagnostics (Basel). 2022;12(4):801. 14. Njei B, Boateng S, Mohamed M, et al. Lean MASLD in U.S. Adults: Undiagnosed Burden and Metabolic Features from NHANES 2017-2020. J Gen Intern Med. 2025 Dec 16. doi: 10.1007/s11606-025-10086-8. 15. Wu S. Reconciling Definitions, Phenotypes and Outcomes in Lean MASLD: Editorial on „Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations“. Clin Mol Hepatol. Published online January 27, 2026. doi:10.3350/cmh.2026.0004. 16. Song SJ, Yoon EL, Wong VW, et al. Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations. Clin Mol Hepatol. Published online December 12, 2025. doi:10.3350/cmh.2025.0851. 17. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52. 18. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. 19. Chen M, Cao Y, Ji G, Zhang L. Lean nonalcoholic fatty liver disease and sarcopenia. Front Endocrinol. 2023;14:1217249. 20. Lu C-W, Chou T-J, Wu T-Y, et al. PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population. Ann Hepatol. 2025;30:101761. 21. Bhattacharya I, Maity DK, Kumar A, et al. Beyond obesity: lean metabolic dysfunction- -associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(10):13647-13665. 22. Sharma B, John S. Nonalcoholic Steatohepatitis (NASH)(Archived). In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 7, 2023. 23. Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: time for action. Diabetes Spectr. 2024;37:9-19. 24. Bianco A, Bonfiglio C, Franco I, et al. Sedentary Behavior as a Risk Factor for Liver Fibrosis Development in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Cross-Sectional Study. J Clin Med. 2025 Oct 24;14(21):7553. 25. Gunn NT. Lean nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Gastroenterol Hepatol (N Y). 2021;17:184-6. 26. Sato-Espinoza K, Chotiprasidhi P, Huaman MR, et al.Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2024;16:452-64. 27. Huo Z, Chen Y, Huang Y, et al. Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. 2025 Oct 15:gutjnl-2025-336127. 28. Dhruv S, Ginnaram S, Fonkam A, et al. Predictors of Development of Hepatocellular Carcinoma in Non-Cirrhotic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis – A Retrospective Analysis of the National Inpatient Sample Database. Gastroenterology Res. 2025 Aug 7;18(5):224-231. 29. Sanyal A J, Newsome P N, KliersI, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. 30. Sanyal AJ, Chalasani N, Kowdley KV, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. 31. Ito D, Shimizu S, Haisa A, et al. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD. J Diabetes Investig. 2024 Sep;15(9):1220-1230. Pro věrné čtenáře Součástí tohoto čísla Vnitřního lékařství je navíc supplementum Zaznělo na 21. interní medicíně pro praxi, které přináší přehledná shrnutí vybraných bloků z jarního kongresu Interní medicína pro praxi v Olomouci. Čtenáři v něm najdou prakticky zaměřené texty věnované například rizikům glukokortikoidy indukované osteoporózy, specifikům léčby hypertenze u pacientů s obezitou a chronickým onemocněním ledvin, diagnostice a terapii primární biliární cholangitidy, možnostem využití atypického anxiolytika či zkušenostem s léčbou mavakamtenem. Supplementum tak připomíná aktuální internistická témata s důrazem na jejich využití v každodenní ambulantní i nemocniční praxi. Věříme, že pro vás návrat k této významné odborné akci bude přínosný a inspirativní.
RkJQdWJsaXNoZXIy NDA4Mjc=